Veronesi Giulia, Bianchi Fabrizio, Infante Maurizio, Alloisio Marco
Division of Thoracic Surgery, Istituto Clinico Humanitas, 20089 Rozzano MI, Italy.
Molecular Medicin Lab, European Institute of Oncology, 20129, Milan, Italy.
Biomark Med. 2016;10(2):137-43. doi: 10.2217/bmm.15.122. Epub 2016 Jan 14.
Various biomarkers have been developed as noninvasive tests to indicate the presence of lung cancer in asymptomatic persons, and in particular to provide evidence as to whether indeterminate lung nodules detected by screening are malignant. We performed an overview of the range of biomarkers reported in the literature and described those that can complement low-dose computed tomography screening. Several have promising sensitivity and specificity. However to our knowledge, only three techniques have reached the prospective screening phase (phase 4) of the five-phase biomarker development process. Two miRNA signatures (the miR-Test for serum and the miRNA signature classifier test for plasma) are being assessed in prospective screening trials, as is the EarlyCDT-Lung test based on autoantibodies. All will need to undergo prospective studies to determine their ability to improve outcomes before they can become an established adjunct to lung cancer control strategies.
已经开发出各种生物标志物作为非侵入性检测手段，以指示无症状人群中肺癌的存在，特别是为筛查发现的肺结节是否为恶性提供证据。我们对文献中报道的生物标志物范围进行了综述，并描述了那些可以补充低剂量计算机断层扫描筛查的生物标志物。其中一些具有良好的敏感性和特异性。然而，据我们所知，在五阶段生物标志物开发过程中，只有三种技术进入了前瞻性筛查阶段（4期）。两种miRNA特征（血清miR-Test和血浆miRNA特征分类器检测）正在前瞻性筛查试验中进行评估，基于自身抗体的EarlyCDT-Lung检测也是如此。在成为肺癌控制策略的既定辅助手段之前，所有这些都需要进行前瞻性研究，以确定它们改善预后的能力。
